ArticleBreast cancer research : BCR2026
Molecular subtypes of breast cancer in Jamaican women: high prevalence of triple-negative and HER2 + disease.
Article in Breast cancer research : BCR, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBreast cancer incidence and mortality patterns vary significantly across populations, with women of African ancestry experiencing disproportionately higher mortality despite lower incidence rates. Jamaica reports concerning breast cancer mortality, yet comprehensive molecular characterization of breast cancer in this predominantly Black Caribbean population remains limited.
methodsWe conducted a retrospective cross-sectional study of 1312 female breast cancer patients diagnosed at the University Hospital of the West Indies in Jamaica between January 2012 and December 2016. Medical records were reviewed for patient demographics, tumour characteristics, and receptor status (estrogen receptor, progesterone receptor, and HER2). Tumours were classified into four molecular subtypes: HR + /HER2- (estrogen receptor positive and/or progesterone receptor positive, HER2 negative), HR + /HER2 + (estrogen receptor positive and/or progesterone receptor positive, HER2 positive), HR-/HER2 + (estrogen receptor negative and progesterone receptor negative, HER2 positive), and triple-negative (HR-/HER2-: estrogen receptor negative and/ progesterone receptor negative, HER2 negative). Bivariate analyses and logistic regression models assessed associations between clinicopathological features and molecular subtypes.
resultsMean age at diagnosis was 55.1 ± 13.6 years. The predominant tumour characteristics were invasive ductal histology (82%), SBR grade 2 (37%), and tumours ≤ 2 cm (31%). Molecular subtype distribution revealed HR + /HER2- (49%), HR + /HER2 + (13%), HR-/HER2 + (12%), and triple-negative (27%). Notably, total HER2 + disease accounted for 25% of cases. Triple-negative tumours were significantly associated higher grade (AOR = 13.92, p < 0.001), and smaller tumours had reduced odds of being triple negative (AOR = 0.47, p < 0.05). Lobular carcinomas showed lower odds of being triple-negative (AOR = 0.17, p < 0.01) compared to ductal carcinomas.
conclusionsJamaican breast cancer patients exhibit a distinctive molecular profile with a high prevalence of both triple-negative (27%) and HER2 + (25%) disease, which likely contributes to poor outcomes in this population. These findings underscore the need for population-specific approaches to breast cancer management in Jamaica, including universal receptor testing and improved access to targeted therapies, particularly anti-HER2 agents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.